EC Number   |
Source Tissue |
Reference |
|---|
   3.4.24.B14 | adrenal gland |
isozymes SEP and SEPDELTA |
651958 |
| 3.4.24.B14 | blood |
peripheral |
733906 |
| 3.4.24.B14 | brain |
- |
690798, 735280 |
| 3.4.24.B14 | brain |
isozymes SEP and SEPDELTA |
651958 |
| 3.4.24.B14 | brain |
NEP2 expression is measured in non-impaired, mild cognitive impaired, and clinical Alzheimer's disease human brain tissue from two Alzheimer's disease -susceptible and two resistant regions. NEP2 and NEP mRNA expression is altered in mild cognitive impaired subjects relative to non-impaired subjects in Alzheimer's disease -susceptible regions. NEP2 enzymatic activity is lowered in association with mild cognitive impaired and Alzheimer's disease and is positively associated with cognitive function, independent of diagnostic category |
717700 |
| 3.4.24.B14 | brain |
NEPII is expressed heterogeneously among several neuronal populations |
690691 |
| 3.4.24.B14 | brain |
while NEP2 is expressed at variable levels in most brain regions, it is most highly expressed in the brain stem, hypothalamus and pituitary |
733906 |
| 3.4.24.B14 | brain |
while NEP2 is expressed at variable levels in most brain regions. Levels of neprilysin-2 mRNA in those with Alzheimer's disease are not different from non-impaired controls |
733906 |
| 3.4.24.B14 | brain stem |
high enzyme level |
733906 |
| 3.4.24.B14 | central nervous system |
- |
754689 |
